153 related articles for article (PubMed ID: 9502370)
1. Prostate-specific antigen testing practices and outcomes.
Hoffman RM; Blume P; Gilliland F
J Gen Intern Med; 1998 Feb; 13(2):106-10. PubMed ID: 9502370
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
3. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
[TBL] [Abstract][Full Text] [Related]
4. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
5. Practitioner-level determinants of inappropriate prostate-specific antigen screening.
Kerfoot BP; Holmberg EF; Lawler EV; Krupat E; Conlin PR
Arch Intern Med; 2007 Jul; 167(13):1367-72. PubMed ID: 17620529
[TBL] [Abstract][Full Text] [Related]
6. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
[TBL] [Abstract][Full Text] [Related]
7. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
[TBL] [Abstract][Full Text] [Related]
8. Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study.
Walsh AL; Considine SW; Thomas AZ; Lynch TH; Manecksha RP
Br J Gen Pract; 2014 Dec; 64(629):e783-7. PubMed ID: 25452543
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists.
Fowler FJ; Bin L; Collins MM; Roberts RG; Oesterling JE; Wasson JH; Barry MJ
Am J Med; 1998 Jun; 104(6):526-32. PubMed ID: 9674714
[TBL] [Abstract][Full Text] [Related]
10. [Estimating standard performance measures of opportunistic screening for prostate cancer].
Leoni M; Falcini F; Ravaioli A; Foca F; Andalò G; Benini F; Dal Pozzo C; Ricci R; Naldoni C; Bucchi L
Epidemiol Prev; 2008; 32(6):285-93. PubMed ID: 19353962
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen testing rates and referral patterns from general practice data in England.
Moss S; Melia J; Sutton J; Mathews C; Kirby M
Int J Clin Pract; 2016 Apr; 70(4):312-8. PubMed ID: 26987766
[TBL] [Abstract][Full Text] [Related]
13. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
14. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
15. Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012.
Wallner LP; Hsu JW; Loo RK; Palmer-Toy DE; Schottinger JE; Jacobsen SJ
Urology; 2015 Sep; 86(3):498-505. PubMed ID: 26123517
[TBL] [Abstract][Full Text] [Related]
16. Delays in prostate cancer care within a hospital network in Victoria, Australia.
Qu LG; Nzenza T; McMillan K; Sengupta S
ANZ J Surg; 2019 Dec; 89(12):1599-1604. PubMed ID: 31786815
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen testing of older men.
Carter HB; Landis PK; Metter EJ; Fleisher LA; Pearson JD
J Natl Cancer Inst; 1999 Oct; 91(20):1733-7. PubMed ID: 10528023
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of delayed clinician response to elevated prostate-specific antigen values.
Nepple KG; Joudi FN; Hillis SL; Wahls TL
Mayo Clin Proc; 2008 Apr; 83(4):439-45. PubMed ID: 18380989
[TBL] [Abstract][Full Text] [Related]
20. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]